BRAF and melanoma: Inhibitors that selectively target mutated B‐RAF such as vemurafenib and dabrafenib have achieved high response rates and been approved for the treatment of melanoma patients with B‐RAFV600E mutation (Ballantyne and Garnock‐Jones, 2013; Bollag et al., 2012).